Cancer Med
Dr. Larry L. Schlabach, MD
- Medicare services, 2024
- 1,798
- Medicare patients, 2024
- 156
- Part D claims, 2024
- 528
- Publications
- 1
- Clinical trials
- 5
- Practice address
- 975 E 3rd St, Chattanooga, TN 37403
- Practice phone
- Call (423) 778-7000
- Professional email
- Get professional email
- Personal email
- Get personal email
- Mobile number
- Get mobile number
Primary practice
Find Dr. Schlabach's professional email, personal email and mobile number
Dmand AI checks each channel through healthcare-specific waterfall enrichment. See what is on file with a free account, with practice phones, licenses and affiliations.
Dr. Larry L. Schlabach is a medical oncologist in Chattanooga, Tennessee
Dr. Schlabach practices at Erlanger Baroness Hospital in Chattanooga, Tennessee, part of Erlanger Health.
Dr. Schlabach's NPI, 1386609394, was assigned on April 20, 2006. Dr. Schlabach graduated from Wright State University Boonshoft School of Medicine in 1987. Dr. Schlabach holds Tennessee license MD00019043.
- NPI
- 1386609394NPI Registry (opens in a new tab)
- Medicare PAC ID
- 9830093822
- NPI enumeration date
- April 20, 2006
- NPI status
- Active
- Accepts Medicare assignment
- Yes
- Practice phone
- (423) 778-7000
- Professional email
- Get email
- Personal email
- Get email
- Mobile number
- Get number
- Sex
- Male
- Estimated age
- 65
- Medical school graduation
- 1987
Sources: NPPES NPI Registry (CMS); Dmand AI Professional Profile Data; Dmand AI Affiliation Data; and Doctors and Clinicians National Downloadable File (CMS)
Dr. Larry L. Schlabach practices at Erlanger Baroness Hospital in Chattanooga, Tennessee
Dr. Schlabach's primary practice is Erlanger Baroness Hospital, at 975 E 3rd St, Chattanooga, TN 37403 in Hamilton County. The practice phone is (423) 778-7000.
- Erlanger Baroness Hospital975 E 3rd St, Chattanooga, TN 37403 · Hamilton CountyPhone(423) 778-7000
Source: Dmand AI Affiliation Data
Dr. Larry L. Schlabach is affiliated with 4 sites of care and 1 medical group
Dr. Schlabach's primary practice is Erlanger Baroness Hospital in Chattanooga, Tennessee, part of Erlanger Health. Dr. Schlabach is also affiliated with CommonSpirit - Memorial Hospital - Chattanooga. The medical group on file is Tennessee Oncology. Dmand AI also links Dr. Schlabach to 1 more community health center and 1 group practice or clinic, each named with a free account.
Sources: Dmand AI Affiliation Data; and Dmand AI Org Hierarchy Data
Dmand AI tracks the EHR system at Dr. Larry L. Schlabach's practice
Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Schlabach practices, 4 sites in all. Vendor and product names are available with a free account.
| Site | EHR vendor and product |
|---|---|
| Erlanger Baroness Hospital | Available with a free account |
| +3 more affiliated sites | Available with a free account |
Source: Dmand AI Technology Install Data
For health IT teams
Dmand AI maps EHR vendors, IT decision makers and buying committees across Erlanger Health and 6.2K+ hospitals, with verified contacts in the same login.
Dr. Larry L. Schlabach is one of 99 medical oncologists in Tennessee
Medical oncology is Dr. Schlabach's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Schlabach is licensed in Tennessee.
Specialties and state licenses
- Medical oncology, TennesseePrimary
Medical oncologists near Dr. Schlabach
Counts of medical oncologists with a Dmand AI profile, by place and practice. Each opens the list.
Sources: NPPES NPI Registry (CMS); Dmand AI Professional Profile Data; and Dmand AI Peer Benchmarks
Dr. Larry L. Schlabach billed Medicare for 1,798 services in 2024
CMS data shows 1,798 Medicare services from Dr. Schlabach across 21 procedure codes in 2024, for 156 Medicare patients. Medicare paid $36,131 for them. Every service was in an office.
Dr. Schlabach's Medicare services by type, 2023 to 2024
- 2023
- 2024
- Lab and pathology
- 2023: 5312024: 67828%
- Drugs given in the office
- 2023: 16,3552024: 42097%
- Surgery
- 2023: 1702024: 24745%
- Office and hospital visits
- 2023: 1702024: 22231%
- Tests and treatments
- 2023: 3182024: 15751%
- Other services
- 2023: 02024: 74
Dr. Schlabach compared with the Tennessee median for medical oncologists, 2024
- Dr. Schlabach
- Tennessee median
- Medicare services
- 1,798vs 1,19451% above
- Medicare patients
- 156vs 23433% below
- Part D claims
- 365vs 370Close to median
Medians across 94 medical oncologists in Tennessee with Dmand AI profiles that report each measure.
Dr. Schlabach's most billed Medicare procedure codes, 2024
CMS publishes codes billed for 11 or more Medicare patients. Each label is the code family; CPT descriptions are licensed by the AMA.
Need commercial claims for Dr. Schlabach?
Medicare shows one payer. Book a meeting to get commercial claims data for Dr. Schlabach and other medical oncologists in Tennessee.
Sources: Medicare Physician & Other Practitioners - by Provider and Service (CMS), 2024 data; and Dmand AI Peer Benchmarks
Dr. Larry L. Schlabach treated 156 Medicare patients in 2024, average age 75
CMS counts 156 Medicare patients who saw Dr. Schlabach in 2024. The largest group is 65 to 74, with 66 patients. 75% of them have high blood pressure, and 68% have high cholesterol. 8% are also on Medicaid. Their average risk score is 1.87, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.
Across all payers, Dmand AI patient panel data puts Dr. Schlabach's median patient age at 66, with 64% women.
Dr. Schlabach's Medicare patients by age, 2024
CMS leaves out age groups with fewer than 11 patients.
Dr. Schlabach's Medicare patients by sex, 2024
- Women9360%
- Men6340%
Chronic conditions among Dr. Schlabach's Medicare patients, 2024
- High blood pressure75%
- High cholesterol68%
- Arthritis54%
- Cancer49%
- Diabetes37%
- Chronic kidney disease35%
- Anxiety32%
- Ischemic heart disease31%
Share of Medicare patients with each condition. A patient can have several.
Dr. Schlabach's patients across all payers
Dmand AI patient panel data covers Medicare, Medicaid and commercial patients.
Patient panel by age, all payers
Median age 66
Patient panel by sex, all payers
- Women64%
- Men36%
Sources: Dmand AI Patient Panel Data; and Medicare Physician & Other Practitioners - by Provider (CMS), 2024 data
Dr. Larry L. Schlabach wrote 528 Medicare Part D claims in 2024
In 2024, Dr. Schlabach wrote 528 Medicare Part D claims for 83 patients. 81% of them were for generic drugs. CMS names the drug for 365 of them, across 14 drugs with 11 or more claims each, at $142,388 in total drug cost. In 2023, CMS named 257 claims across 15 drugs.
Dr. Schlabach's Part D claims by kind of drug, 2024
- Generic428 claims81%
- Brand-name100 claims19%
Dr. Schlabach's most prescribed drugs by claims, 2024
CMS names a drug when it has 11 or more claims. Share is of the claims for drugs CMS names.
Drug classes CMS tracks in Dr. Schlabach's Part D claims, 2024
- Opioids7%38 of 528 claims
Share of all Part D claims for each drug class CMS reports on. Classes with no claims are left out.
Part D claims for drugs CMS names, 2023 to 2024
- 2023
- 2024
- Claims for drugs CMS names
- 2023: 2572024: 36542%
Drugs named by CMS: 14 in 2024, 15 in 2023.
Sources: Medicare Part D Prescribers - by Provider and Drug (CMS), 2024 data, released May 6, 2026; and Medicare Part D Prescribers - by Provider (CMS), 2024 data
Dr. Larry L. Schlabach scored 93 out of 100 in Medicare's MIPS program for 2024
CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Schlabach for performance year 2024, reported as part of a group. Dr. Schlabach accepts Medicare assignment, so Medicare's approved amount is taken as full payment.
- Accepts Medicare assignment
- Yes
Dr. Schlabach's MIPS scores, performance year 2024
- 93of 100Final score
- 89of 100Promoting Interoperability
- 40of 100Improvement Activities
Each score is out of 100. The final score weighs the categories CMS scored for this clinician.
Sources: Doctors and Clinicians National Downloadable File (CMS); and Clinician Public Reporting: Overall MIPS Performance (CMS), 2024 data, released September 10, 2026
For MedTech and pharma teams
Filter 7.4M+ HCPs by Medicare procedures, Part D drugs and Open Payments history, then reach them with verified contacts in one login.
Dr. Larry L. Schlabach has 1 publication on record
Dmand AI links 1 paper to Dr. Schlabach in 2014. Dr. Schlabach's most frequent co-authors are Russell Foster Devore, MD, Laura Williams Goff, MD and Charles F. Winkler, MD.
Dr. Schlabach's most frequent co-authors
- Russell Foster Devore, MD1 shared paper
- Laura Williams Goff, MD1 shared paper
- Charles F. Winkler, MD1 shared paper
Recent publications by Dr. Schlabach
See who Dr. Schlabach researches with
Physician Network Discovery turns co-authorship, shared hospitals and shared groups into a map of who Dr. Schlabach works with, so you can find a warm path to the right medical oncologists.
Sources: PubMed (National Library of Medicine); and Dmand AI Research Linkage
Dr. Larry L. Schlabach has worked on 5 clinical trials
Dmand AI links Dr. Schlabach to 5 clinical trials, 4 of them phase 3 studies. 4 are still active or recruiting. Conditions studied include Breast Neoplasms, Breast Neoplasms, Male and Leukemia, Megakaryoblastic, Acute. SWOG Cancer Research Network sponsors the most, 2. Open Payments lists research payments to Dr. Schlabach that name 1 trial.
Conditions in Dr. Schlabach's trials
- Breast Neoplasms
- Breast Neoplasms, Male
- Leukemia, Megakaryoblastic, Acute
- Melanoma
- Prostatic Neoplasms
Investigators on the most trials with Dr. Schlabach
- Carla I. Falkson, MD3 shared trials
- Henry Gerad, MD3 shared trials
- Gilbert D. A. Padula, MD3 shared trials
Recent clinical trials with Dr. Schlabach
Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma (opens in a new tab)
S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer (opens in a new tab)
S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer (opens in a new tab)
Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer (opens in a new tab)
Sources: Open Payments (CMS), 2025 data, released July 7, 2026; Dmand AI Research Linkage; and ClinicalTrials.gov (National Library of Medicine)
Dr. Larry L. Schlabach received $572 in industry payments from 2018 to 2025
CMS Open Payments shows 24 general payments to Dr. Schlabach from 15 drug and device companies from 2018 to 2025. Food and beverage make up the largest share, 69% of the total. Janssen Pharmaceuticals, Inc paid the most, $114. It also lists 1 research payment totaling $450 in 2018, naming 1 clinical trial.
General payments to Dr. Schlabach by program year, 2018 to 2025
General payments to Dr. Schlabach by kind, 2018 to 2025
- Food and beverage$39769%
- Education$17531%
Companies that paid Dr. Schlabach the most, 2018 to 2025
Share is of all general payments to this clinician.
Source: Open Payments (CMS), 2025 data, released July 7, 2026
Dr. Larry L. Schlabach graduated from Wright State University Boonshoft School of Medicine
Dr. Schlabach graduated from Wright State University Boonshoft School of Medicine in 1987.
- Medical school
Source: Dmand AI Professional Profile Data
Sources for Dr. Larry L. Schlabach's profile data
| Data on this page | Source |
|---|---|
| NPI, name, sex, specialty and licenses | NPPES NPI Registry (CMS) (opens in a new tab)Dmand AI Professional Profile Data |
| Practice locations and phone | Dmand AI Affiliation Data |
| Primary practice, affiliations and health system | Dmand AI Affiliation DataDmand AI Org Hierarchy Data |
| Medicare services and procedure codes | Medicare Physician & Other Practitioners - by Provider and Service (CMS) (opens in a new tab) |
| State medians for the same specialty | Dmand AI Peer Benchmarks |
| Medicare patients and the all-payer patient panel | Dmand AI Patient Panel DataMedicare Physician & Other Practitioners - by Provider (CMS) (opens in a new tab) |
| Part D prescribing | Medicare Part D Prescribers - by Provider and Drug (CMS) (opens in a new tab)Medicare Part D Prescribers - by Provider (CMS) (opens in a new tab) |
| MIPS scores, telehealth, assignment and procedure percentiles | Doctors and Clinicians National Downloadable File (CMS) (opens in a new tab)Clinician Public Reporting: Overall MIPS Performance (CMS) (opens in a new tab) |
| Publications, topics and co-authors | PubMed (National Library of Medicine) (opens in a new tab)Dmand AI Research Linkage |
| Clinical trials and co-investigators | Dmand AI Research LinkageClinicalTrials.gov (National Library of Medicine) (opens in a new tab) |
| Industry payments | Open Payments (CMS) (opens in a new tab) |
| Training, board certification and memberships | Dmand AI Professional Profile Data |
| EHR at each practice site | Dmand AI Technology Install Data |
| Similar physicians | Dmand AI Affiliation Data |
Data last refreshed October 2026Report an inaccuracyRemove my information
FAQ
Frequently asked questions about Dr. Larry L. Schlabach
Spotted something out of date? Email hello@dmand.ai and we will check the record. Contact details live in the free trial.
What is Dr. Larry L. Schlabach's NPI number?
Dr. Larry L. Schlabach's NPI number is 1386609394. It was assigned on April 20, 2006, and it is active in the NPI Registry.
What kind of doctor is Dr. Larry L. Schlabach?
Dr. Larry L. Schlabach is a medical oncologist in Chattanooga, Tennessee. The primary specialty in the NPI Registry is Medical Oncology Physician (taxonomy code 207RX0202X).
Where does Dr. Larry L. Schlabach practice?
Dr. Schlabach practices at 975 E 3rd St, Chattanooga, TN 37403. Dr. Schlabach's primary practice is Erlanger Baroness Hospital in Chattanooga, Tennessee, part of Erlanger Health. Dmand AI also links Dr. Schlabach to 1 community health center and 1 group practice or clinic.
What is Dr. Larry L. Schlabach's office phone number?
The practice phone on file for Dr. Schlabach is (423) 778-7000.
What is Dr. Larry L. Schlabach's medical license number?
Dr. Schlabach holds Tennessee license MD00019043.
Which hospitals is Dr. Larry L. Schlabach affiliated with?
Dr. Schlabach practices at Erlanger Baroness Hospital in Chattanooga, Tennessee. Dr. Schlabach is also affiliated with CommonSpirit - Memorial Hospital - Chattanooga.
What medical group is Dr. Larry L. Schlabach part of?
Dr. Schlabach is linked to Tennessee Oncology.
Does Dr. Larry L. Schlabach accept Medicare?
Yes. CMS data shows Dr. Schlabach billed Medicare for 1,798 services in 2024, and Dr. Schlabach accepts Medicare assignment.
What is Dr. Larry L. Schlabach's MIPS score?
Dr. Schlabach's MIPS final score for performance year 2024 is 93 out of 100, reported as part of a group.
How many Medicare patients does Dr. Larry L. Schlabach see?
CMS counts 156 Medicare patients who saw Dr. Schlabach in 2024, with an average age of 75.
Show 7 more questionsShow fewer questions
What services does Dr. Larry L. Schlabach bill to Medicare?
In 2024, Dr. Schlabach's most billed Medicare services were injected or infused drug (J1100), lab and pathology test (85025) and surgery: heart and blood vessels (36415).
Where did Dr. Larry L. Schlabach go to medical school?
Dr. Schlabach graduated from Wright State University Boonshoft School of Medicine in 1987.
What drugs does Dr. Larry L. Schlabach prescribe most?
In 2024 Medicare Part D data, Dr. Schlabach's most prescribed drugs by claims were Anastrozole, Abiraterone Acetate and Prednisone.
Has Dr. Larry L. Schlabach received payments from drug or device companies?
CMS Open Payments shows $572 in general payments to Dr. Schlabach from 15 companies from 2018 to 2025. The largest total came from Janssen Pharmaceuticals, Inc.
How long has Dr. Larry L. Schlabach been practicing?
Dr. Schlabach graduated from medical school in 1987, 39 years ago.
Does Dr. Larry L. Schlabach do research?
Dmand AI links 1 publication to Dr. Schlabach. Dr. Schlabach has worked on 5 clinical trials.
Who does Dr. Larry L. Schlabach publish with?
Dr. Schlabach's most frequent co-authors are Russell Foster Devore, MD (1 shared paper), Laura Williams Goff, MD (1 shared paper) and Charles F. Winkler, MD (1 shared paper).
Selling to medical oncology practices?
See medical oncologists in Tennessee by site of care and group
Find the practices, groups and hospitals they work with, and the right people to contact at each.
- 30 days free
- Self-serve
- No credit card